Management of unresectable locoregionally advanced and metastatic nonsquamous NSCLC

American Journal of Pharmacy Benefits

Volumn 3, Issue 2, 2011, Pages 89-93

  Bergstrom, Kimberly A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b McKesson   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED;

ADVANCED CANCER; ANOREXIA; ARTICLE; ASTHENIA; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DIARRHEA; DISSEMINATED CANCER; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEMATEMESIS; HEMOPTYSIS; HUMAN; INFECTION; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PATIENT CARE; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

EID: 84859757685     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Govinda R, Bogart J, Wang X, Liu D, Kratzke RA, Vokes EE. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407-early evaluation of feasibility and toxicity [abstract]. J Clin Oncol, 2008 ASCO Annual Meeting. 2008;26(May 20 suppl):7518.
2. Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIb non-small-cell lung cancer: a South- west Oncology Group Phase II study, SWOG 9019. J Clin Oncol. 2002;20(16): 3454-3460.
3. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol [published correction appears in J Clin Oncol. 2006;24(12):1966]. J Clin Oncol. 2005;23(25):5883-5891.
4. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004;292(4):470-484.
5. Paccagnella A, Oniga F, Bearz A, et al. Adding gemcitabine to paclitaxel/carbo platin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study [published correction appears in J Clin Oncol. 2006; 24(14):2220]. J Clin Oncol. 2006; 24(4):681-687.
6. Comella P, Filippelli G, De Cataldis G, et al; Southern Italy Cooperative Oncology Group. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol. 2007;18(2)324-330.
7. Ardizzoni A, Boni I, Tiseo M, et al; CISCA (CISplatin versus CArboplatin) Meta- analysis Group. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta- analysis. J Natl Cancer Inst. 2007;99(11):847-857.
8. UpToDate, v 18.2. May 2010. http://www.uptodate.com. Accessed September 10, 2010.
9. Hanna N, Shepherd FA, Fossella F, et al. Randomized phase III trial of peme- trexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597.
10. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21): 3543-3551.
11. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23(13):2937-2945.
12. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003; 21(16):3016-3024.
13. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol. 2005;23(1):142-153.
14. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cispla- tin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18(2):317-323.
15. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevaci zumab for non-small-cell lung cancer [published correction appears in N Engl J Med. 2007;356(3):318]. N Engl J Med. 2006;355(24):2542-2550.
16. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small cell lung cancer. J Clin Oncol. 2009;27(19):3217-3224.
17. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009;27(18S, June 20 suppl): CRA8000.
18. Cappuzzo F, Ciuleanu T, Stelmakh L, et al; the SATURN Investigators. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC [abstract]. J Clin Oncol, 2009 ASCO Annual Meeting Pro- ceedings (Post-Meeting Edition). 2009; 27(15S, May 20 suppl):8001.
19. Pirker R, Pereira JR, Szczesna A, et al; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373(9674):1525-1531.
20. Miller VA, O' Connor P, Soh C, Kabbinavar F; ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009;27(18S, June 20 suppl): LBA8002.